Making a diagnosis in PAH

Autor: J. S. R. Gibbs

Publikováno v: European Respiratory Review, Vol 16, Iss 102, Pp 8-12 (2007)

Poor survival among patients with untreated pulmonary arterial hypertension (PAH) means that timely and accurate diagnosis is of paramount importance. However, the nonspecific nature of PAH symptoms, which include breathlessness and fatigue, make PAH

Externí odkaz: https://doaj.org/article/c27995edb2404782bdbced5ccecfddf5

S94 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON

Autor: N Galie, Marius M. Hoeper, Kelly Chin, Loïc Perchenet, O. Sitbon, Stephen C. Mathai, Luke Howard, Vallerie V. McLaughlin, Mylene Stefani, Martin Doelberg, J S R Gibbs, G. Simonneau

Publikováno v: Pulmonary arterial hypertension: drugs, sox and cytokines.

Introduction and Objectives In the randomized controlled TRITON (NCT02558231) study, both initial triple oral (macitentan, tadalafil, selexipag) and initial double oral (macitentan, tadalafil, placebo) therapy improved pulmonary vascular resistance (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a8c4b903a8d027233fa68efda1bf23e
https://doi.org/10.1136/thorax-2020-btsabstracts.99

S40 Phenotypic characterisation of GDF2 mutation carriers in a large cohort of patients with pulmonary arterial hypertension

Autor: Nicholas W. Morrell, Jay Suntharalingam, Marc Humbert, Marta Bleda, Shahin Moledina, Luke Howard, Richard C. Trembath, A. Vonk Noordegraaf, M Jonson, James Lordan, Andrew J. Peacock, Robin Condliffe, J S R Gibbs, Colin Church, Stefan Gräf, Toshner, Wilkins, Paul A. Corris, Charaka Hadinnapola, Allan Lawrie, Simon Holden, Emilia M. Swietlik, Werner Seeger, Gerry Coghlan, Joshua Hodgson, Stephen J. Wort, David G. Kiely, John Wharton, Paul D. Upton, Joanna Pepke-Zaba, Horst Olschewski, Matthias Haimel, R.V. MacKenzie Ross

Publikováno v: Fundamental mechanisms of pulmonary arterial hypertension.

Introduction A major breakthrough in the understanding the pathobiology of pulmonary arterial hypertension (PAH) was the identification of heterozygous disease-causing mutations in the BMPR2gene. Recently, mutations were also identified in GDF2, whic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c3686eaab40f0d36a58aabe2c3850f1
https://doi.org/10.1136/thorax-2018-212555.46

Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension

Autor: Shahin Moledina, Christopher J. Rhodes, J Suntharalingam, Emilia M. Swietlik, Gerry Coghlan, S. Provencher, Andrew J. Peacock, Charaka Hadinnapola, R Condliffe, Carmen M. Treacy, Joanna Pepke-Zaba, Matthew D. Johnson, John Wharton, E. Di Angelantonio, Allan Lawrie, Michael Newnham, James Lordan, Stephen J. Wort, Laura C. Price, Luke S. Howard, David G. Kiely, Eleni Sofianopoulou, Martin R. Wilkins, Stephen Kaptoge, Jennifer M. Martin, Nicholas W. Morrell, Paul A. Corris, R.V. MacKenzie Ross, Matthias Haimel, J S R Gibbs, Mark Toshner, Colin Church, Stefan Gräf

Publikováno v: Environmental Epidemiology. 3:376

While traffic and air pollution exposure is associated with increased mortality in numerous diseases, its association with disease severity and outcomes in pulmonary arterial hypertension (PAH) remains unknown.Exposure to particulate matter ≤2.5 μ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea8ebedc95d274cd2c18d55dec584de4
https://doi.org/10.1097/01.ee9.0000610184.58135.60

Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target

Autor: Christopher J. Rhodes, J S R Gibbs, J Wharton, A. Vonk-Noordegraaf, L Howard, Martin R. Wilkins

Publikováno v: Rhodes, C J, Wharton, J, Howard, L, Gibbs, J S R, Vonk Noordegraaf, A & Wilkins, M R 2011, ' Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target ', European Respiratory Journal, vol. 38, no. 6, pp. 1453-1460 . https://doi.org/10.1183/09031936.00037711
European Respiratory Journal, 38(6), 1453-1460. European Respiratory Society

Iron deficiency is known to be common and detrimental in chronic left heart failure, where parenteral iron treatment has been shown to improve exercise capacity, New York Heart Association functional class and patient wellbeing. There is now increasi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b30e1d70a47b194c46eebe4e248fb1d
https://doi.org/10.1183/09031936.00037711